STK17A (serine/threonine kinase 17a) is a member of the death-associated protein kinase family that functions as a positive regulator of apoptosis 1 and modulates cellular reactive oxygen species. The protein exhibits ATP-dependent kinase activity and operates through intracellular signaling pathways, localizing primarily to the nucleus with translocation to the cytoplasm following DNA damage 2. STK17A plays a dual role in cancer biology with context-dependent functions. In colorectal cancer, decreased STK17A expression correlates with metastatic progression; loss of STK17A induces epithelial-mesenchymal transition, increased invasion, and migration through mechanisms independent of apoptosis regulation 3. Conversely, in glioblastoma and gastric cancer, STK17A overexpression promotes cell proliferation, migration, and invasion, with high expression associated with poor prognosis and survival disadvantage 4 5. Clinically, STK17A polymorphisms associate with systemic lupus erythematosus susceptibility and disease manifestations including arthritis and cutaneous alterations 6. Additionally, increased STK17A expression characterizes centenarians' immune cells, suggesting involvement in DNA damage response and adaptive immunity associated with exceptional longevity 7. In cervical cancer, the miR-411/STK17A axis regulates radiotherapy efficacy through p53 pathway activation, where STK17A suppression enhances treatment response 8. These findings identify STK17A as a therapeutic target with biomarker potential across multiple malignancies.